GSK, Global Real-World Evidence & Health Outcomes Research
Wyoming, OH, United States
Director – Specialty/Immunology
US Value, Evidence and Outcomes (US VEO)
2456: Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): GlaxoSmithKlein(GSK): Employee (Ongoing), Equity interest (Ongoing)
